BioDelivery Sciences International Inc. (NASDAQ:BDSI) was up 9.4% on Friday . The stock traded as high as $2.60 and last traded at $2.57, with a volume of 1,269,093 shares trading hands. The stock had previously closed at $2.35.

Several equities research analysts have recently weighed in on BDSI shares. FBR & Co increased their price objective on BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a report on Wednesday, May 4th. Zacks Investment Research downgraded BioDelivery Sciences International from a “hold” rating to a “strong sell” rating in a report on Friday, May 6th. Cantor Fitzgerald downgraded BioDelivery Sciences International from a “buy” rating to a “hold” rating and decreased their price objective for the company from $9.00 to $5.00 in a report on Wednesday, May 11th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $4.00 price objective (down from $6.00) on shares of BioDelivery Sciences International in a report on Thursday, May 12th. Finally, Janney Montgomery Scott reissued a “hold” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a report on Tuesday, July 12th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $8.25.

The stock has a 50-day moving average of $2.44 and a 200-day moving average of $3.06. The firm’s market capitalization is $136.66 million.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.01. The business earned $3 million during the quarter, compared to the consensus estimate of $2.96 million. During the same quarter in the previous year, the company earned ($0.16) EPS. The firm’s revenue was down 77.1% compared to the same quarter last year. On average, equities analysts expect that BioDelivery Sciences International Inc. will post ($1.17) EPS for the current fiscal year.

A number of large investors have bought and sold shares of the company. 1492 Capital Management LLC increased its stake in BioDelivery Sciences International by 8.3% in the fourth quarter. 1492 Capital Management LLC now owns 538,538 shares of the specialty pharmaceutical company’s stock valued at $2,580,000 after buying an additional 41,069 shares in the last quarter. Turner Investments L.P. raised its position in shares of BioDelivery Sciences International by 55.4% in the fourth quarter. Turner Investments L.P. now owns 900,830 shares of the specialty pharmaceutical company’s stock valued at $4,315,000 after buying an additional 321,290 shares during the last quarter. Bank of Montreal Can raised its position in shares of BioDelivery Sciences International by 3.6% in the fourth quarter. Bank of Montreal Can now owns 829,056 shares of the specialty pharmaceutical company’s stock valued at $3,971,000 after buying an additional 28,838 shares during the last quarter. Sei Investments Co. raised its position in shares of BioDelivery Sciences International by 240.1% in the fourth quarter. Sei Investments Co. now owns 330,789 shares of the specialty pharmaceutical company’s stock valued at $1,584,000 after buying an additional 233,519 shares during the last quarter. Finally, Russell Frank Co raised its position in shares of BioDelivery Sciences International by 57.5% in the fourth quarter. Russell Frank Co now owns 1,080,051 shares of the specialty pharmaceutical company’s stock valued at $5,151,000 after buying an additional 394,272 shares during the last quarter.

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.